EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes

Yasaman Iranmanesh, Noha Omar, Arya Rasouli, Alex Baras, Sergiu Pasca, Lukasz P Gondek, Hua-Ling Tsai, Samuel R Denmeade, Michael A Carducci, Channing J Paller, Mark C Markowski, Jun Luo und 3 weitere

The Oncologist · 04.04.2025 · 30 (4)

DOI: 10.1093/oncolo/oyaf049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 22.04.2025. Verfasst von Yasaman Iranmanesh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Clonal Hematopoiesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Winn Career Development, V Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clonal hematopoiesis (CH) may be inferred from clinical next-generation sequencing (NGS) of tumor tissue. The clinical significance of inferred CH when detected as part of routine tumor sequencing is not well established and it is unknown whether or not CH is associated with other somatic mutations in tumors of men with prostate cancer.

Methods

We performed a retrospective review of clinical-grade NGS results from primary prostate tissue at a single institution. NGS reports were reviewed for the presence of pathogenic mutations in a panel of 27 genes commonly known to be mutated in CH. Overall survival from time of diagnosis and association with somatic alterations were interrogated.

Results

A total of 396 patients were included, with a median follow-up of 7.8 years (range 0.2-21.4 years). Approximately 12% of patients had inferred CH detected (n = 46) with ASXL1, TET2, and DNMT3A being the most commonly affected genes. In univariate analysis, those with inferred CH had an 81% increased risk of death compared to those without inferred CH (hazard ratio 1.8, 95% CI 1.1, 3.1, P = .03). This was attenuated after controlling for age at diagnosis and race (HR 1.1, 95% CI 0.6, 2.0, P = .77). Those with inferred CH were more likely to have pathogenic somatic mutations in PIK3CA (15% vs 4%), CTNNB1 (13% vs 2%) and BRCA1 (4% vs 0.3%).

Conclusion

Inferred CH is commonly detected on tumor-tissue NGS testing but does not clearly have a negative prognostic impact after adjusting for age. It may also be associated with the identification of other somatic driver mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsClonal HematopoiesisHumansMaleAgedMiddle AgedHigh-Throughput Nucleotide SequencingMutationRetrospective StudiesAged, 80 and overSequence Analysis, DNAPrognosisAdultDNA Methyltransferase 3A

Stichwörter der Autor:innen

clonal hematopoiesis of indeterminate potentialnext generation DNA sequencingprostate cancertumor biopsies

Substanzen

DNA Methyltransferase 3A

Autor:innen und Institutionen

  • Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
  • UPMC Western Maryland, Department of Internal Medicine. Cumberland, MD 21502, United States.
  • Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, United States.

ORCID-Profile: Catherine H Marshall

Förderung

  • NCI NIH HHS
  • Winn Career Development
  • V Foundation
  • Prostate Cancer Foundation
  • Department Of Defense
  • National Cancer Institute

Zitieren

APA

Iranmanesh, Y., Omar, N., Rasouli, A., Baras, A., Pasca, S., Gondek, L. P., Tsai, H. L., Denmeade, S. R., Carducci, M. A., Paller, C. J., Markowski, M. C., Luo, J., Eisenberger, M. A., Antonarakis, E. S., & Marshall, C. H. (2025). Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes. The Oncologist, 30(4). https://doi.org/10.1093/oncolo/oyaf049

Vancouver

Iranmanesh Y, Omar N, Rasouli A, Baras A, Pasca S, Gondek LP, et al. Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes. The Oncologist. 2025;30(4). doi:10.1093/oncolo/oyaf049

BibTeX
@article{Iranmanesh2025,
  author = {Iranmanesh, Yasaman and Omar, Noha and Rasouli, Arya and Baras, Alex and Pasca, Sergiu and Gondek, Lukasz P and Tsai, Hua-Ling and Denmeade, Samuel R and Carducci, Michael A and Paller, Channing J and Markowski, Mark C and Luo, Jun and Eisenberger, Mario A and Antonarakis, Emmanuel S and Marshall, Catherine H},
  title = {Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {4},
  doi = {10.1093/oncolo/oyaf049}
}
Kostenlos starten →